BIO Issues Statement on President Trump's Signing of FDA Reauthorization Act
August 18, 2017
August 18, 2017
WASHINGTON, Aug. 18 -- The Biotechnology Innovation Organization issued the following statement by President and CEO James C. Greenwood on President Trump's signing of the Food and Drug Administration Reauthorization Act:
"President Trump's signature today on this landmark legislation is the culmination of a years-long collaborative process in which patients, industry, FDA, legislators and other stakeholders worked tirelessly to identify ways in which FDA's human drug review pr . . .
"President Trump's signature today on this landmark legislation is the culmination of a years-long collaborative process in which patients, industry, FDA, legislators and other stakeholders worked tirelessly to identify ways in which FDA's human drug review pr . . .